AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18023787 — intervention group
Group type: EXPERIMENTAL
Intervention: multiple behavior health contract
Number of subjects: 155
Study 18023787 — intervention group
Group type: EXPERIMENTAL
Intervention: one‐on‐one tailored consultation
Number of subjects: 155
Study 18023787 — intervention group
Group type: EXPERIMENTAL
Intervention: combined consultation plus contract intervention
Number of subjects: 155
Study 18023787 — intervention group
Group type: EXPERIMENTAL
Intervention: consultation or consultation plus contract
Number of subjects: 155
Study 15771029 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (synthetic prostacyclin analogue)
Number of subjects: 30
Study 15771029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12472618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream 5% applied for 20 min
Number of subjects: 40
Study 12472618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream 5% applied for 30 min
Number of subjects: 40
Study 12472618 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream 5% applied for 45 min
Number of subjects: 40
Study 12472618 — intervention group
Group type: COMPARATOR
Intervention: Base cream as placebo
Number of subjects: 40
Study 18653121 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid treatment for 60 days
Number of subjects: 30
Study 18653121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7808833 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural change from supine to standing position
Number of subjects: 20
Study 2573295 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion after placebo pretreatment
Number of subjects: 12
Study 2573295 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion after atenolol pretreatment
Number of subjects: 12
Study 2573295 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion after propranolol pretreatment
Number of subjects: 12
Study 2573295 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusion after beta-2-selective beta-blocking agent (ICI 118551)
Number of subjects: 12
Study 805621 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 100
Study 805621 — intervention group
Group type: COMPARATOR
Intervention: Control (no antibiotic)
Number of subjects: 100
Study 29561428 — intervention group
Group type: EXPERIMENTAL
Intervention: ChondroT 1.0 g
Number of subjects: 0
Study 29561428 — intervention group
Group type: EXPERIMENTAL
Intervention: ChondroT 2.0 g
Number of subjects: 0
Study 29561428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28205449 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRK2 and COMT SNP genotypes
Number of subjects: 51
Study 28205449 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT variants
Number of subjects: 51
Study 28205449 — intervention group
Group type: EXPERIMENTAL
Intervention: NTRK2 SNP rs1212171 genotype
Number of subjects: 51
Study 25342376 — intervention group
Group type: EXPERIMENTAL
Intervention: ENT involvement
Number of subjects: 414
Study 25342376 — intervention group
Group type: EXPERIMENTAL
Intervention: Each added ENT symptom
Number of subjects: 414
Study 25342376 — intervention group
Group type: COMPARATOR
Intervention: Other early disease manifestations (arthralgia/arthritis, cutaneous and lung involvement)
Number of subjects: 414
Study 23506049 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based program for preventing generalised anxiety, supervised by classroom teachers, completed during class periods over six weeks.
Number of subjects: 30
Study 23506049 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based program for preventing generalised anxiety, supervised by classroom teachers and an education officer from the local youth mental health centre, completed during class periods over six weeks.
Number of subjects: 30
Study 23506049 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition (no intervention).
Number of subjects: 30
Study 22081994 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex quality improvement intervention for GPs
Number of subjects: 0
Study 22081994 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0
Study 18652270 — intervention group
Group type: EXPERIMENTAL
Intervention: All Bond 2
Number of subjects: 0
Study 18652270 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-Bond
Number of subjects: 0
Study 18652270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 0
Study 18652270 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno III
Number of subjects: 0
Study 18652270 — intervention group
Group type: COMPARATOR
Intervention: Pre-Bond unfilled resin of All Bond 2 without primer application
Number of subjects: 0
Study 16766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Close friends' smoking
Number of subjects: 4576
Study 16766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' smoking
Number of subjects: 4576
Study 16766414 — intervention group
Group type: EXPERIMENTAL
Intervention: Older siblings' smoking
Number of subjects: 4576
Study 12712245 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g resistant starch (Novelose 260)
Number of subjects: 10
Study 12712245 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no resistant starch)
Number of subjects: 10
Study 10825109 — intervention group
Group type: EXPERIMENTAL
Intervention: THA using the intraoperative limb-length measuring device (Group B)
Number of subjects: 117
Study 10825109 — intervention group
Group type: COMPARATOR
Intervention: THA without the measuring device (Group A)
Number of subjects: 117
Study 8658094 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/h)
Number of subjects: 121
Study 8658094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 1996871 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (curative resection or palliative resection)
Number of subjects: 31
Study 1996871 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (5000 cGy in 20 fractions over 4 weeks or 6000 cGy in 30 fractions over 6 weeks)
Number of subjects: 31
Study 6337668 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intermittent calf compression
Number of subjects: 90
Study 6337668 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 90
Study 6337668 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Charnley technique
Number of subjects: 90
Study 6337668 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior surgical approach
Number of subjects: 90
Study 31427472 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 6
Study 31427472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29194764 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 minutes of physical education per week
Number of subjects: 228
Study 26886423 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure
Number of subjects: 63
Study 26886423 — intervention group
Group type: COMPARATOR
Intervention: Augmented Reality exposure
Number of subjects: 63
Study 24451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene-enriched diet (20-25 mg/day of lycopene; through 30 g/day of triple concentrated tomato paste) for 6 months
Number of subjects: 32
Study 24451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PSA levels
Number of subjects: 32
Study 24451130 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate of HGPIN progression to PC
Number of subjects: 32
Study 22632574 — intervention group
Group type: EXPERIMENTAL
Intervention: Early parenteral nutrition (Early-PN)
Number of subjects: 4640
Study 20145061 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillators (ICDs)
Number of subjects: 0
Study 20145061 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17716779 — intervention group
Group type: EXPERIMENTAL
Intervention: BLM (1mg/kg, max 60mg/body)
Number of subjects: 102
Study 17716779 — intervention group
Group type: EXPERIMENTAL
Intervention: OK-432 (0.2 KE/kg, max 10KE/body)
Number of subjects: 102
Study 17716779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (80mg/m2) and Etoposide (80mg/m2)
Number of subjects: 102
Study 15533546 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraplegics
Number of subjects: 32
Study 15533546 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraplegics
Number of subjects: 32
Study 15533546 — intervention group
Group type: COMPARATOR
Intervention: Control persons
Number of subjects: 32
Study 15533546 — intervention group
Group type: EXPERIMENTAL
Intervention: Female tetraplegics
Number of subjects: 32
Study 12051113 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and sequential levonorgestrel (50 micrograms/day estradiol for 2 weeks followed by 50 micrograms/day estradiol-10 micrograms/day levonorgestrel for 2 weeks)
Number of subjects: 468
Study 12051113 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and sequential levonorgestrel (75 micrograms/day estradiol for 2 weeks followed by 75 micrograms/day estradiol-15 micrograms/day levonorgestrel for 2 weeks)
Number of subjects: 468
Study 12051113 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and sequential levonorgestrel (100 micrograms/day estradiol for 2 weeks followed by 100 micrograms/day estradiol-20 micrograms/day levonorgestrel for 2 weeks)
Number of subjects: 468
Study 12051113 — intervention group
Group type: EXPERIMENTAL
Intervention: All three doses of the transdermal hormone replacement therapy
Number of subjects: 468
Study 10354975 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 350 V shock (15 pts)
Number of subjects: 30
Study 10354975 — intervention group
Group type: COMPARATOR
Intervention: Multiple shocks of increasing energy (15 pts)
Number of subjects: 30
Study 8652176 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with appropriate selection of drugs, techniques, and needles
Number of subjects: 0
Study 1741639 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 0
Study 1741639 — intervention group
Group type: COMPARATOR
Intervention: Hot water
Number of subjects: 0
Study 1741639 — intervention group
Group type: COMPARATOR
Intervention: No fluid
Number of subjects: 0
Study 6805714 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage and primary suture
Number of subjects: 114
Study 6805714 — intervention group
Group type: COMPARATOR
Intervention: Simple drainage
Number of subjects: 114
Study 29433682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol extract of sage, rosemary and melissa (SRM)
Number of subjects: 44
Study 29433682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ethanol extract of Myrrhis odorata)
Number of subjects: 44
Study 26198890 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilisation (n=43) consisting of early and frequent out of bed activities starting within 24 hours of stroke onset for 5 to 30 minutes at least twice a day for seven days
Number of subjects: 86
Study 26198890 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilisation (n=43)
Number of subjects: 86
Study 26198890 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=43)
Number of subjects: 86
Study 25706622 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes moderate-intensity aerobic and resistance exercise five days/week over 24 weeks (one supervised and four unsupervised sessions)
Number of subjects: 33
Study 25706622 — intervention group
Group type: COMPARATOR
Intervention: 45 minutes stretching five days/week over 24 weeks (one supervised and four unsupervised sessions)
Number of subjects: 33
Study 23602230 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder without zinc (group B)
Number of subjects: 2746
Study 23602230 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder with zinc (group C)
Number of subjects: 2746
Study 23602230 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented control (group A)
Number of subjects: 2746
Study 23602230 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powder groups (B and C)
Number of subjects: 2746
Study 20800968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral minimal contact program (MCT)
Number of subjects: 182
Study 20800968 — intervention group
Group type: COMPARATOR
Intervention: Brochure (bibliotherapy)
Number of subjects: 182
Study 18757184 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular polysaccharide-based vaccine (StaphVAX)
Number of subjects: 0
Study 18757184 — intervention group
Group type: EXPERIMENTAL
Intervention: Human immunoglobulin G (IgG) preparation (INH-A21, Veronate)
Number of subjects: 0
Study 18757184 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antigens in pre-clinical trials
Number of subjects: 0
Study 16024184 — intervention group
Group type: EXPERIMENTAL
Intervention: RODA
Number of subjects: 70
Study 16024184 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 70
Study 15518609 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with CHF
Number of subjects: 1591
Study 15518609 — intervention group
Group type: COMPARATOR
Intervention: Men with CHF
Number of subjects: 1591
Study 10920157 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol administered through the spacer device (50 microg/kg)
Number of subjects: 64
Study 10920157 — intervention group
Group type: COMPARATOR
Intervention: Albuterol administered through the nebulizer (150 microg/kg)
Number of subjects: 64
Study 10920157 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol administered through the spacer device
Number of subjects: 64
Study 10920157 — intervention group
Group type: COMPARATOR
Intervention: Albuterol administered through the nebulizer
Number of subjects: 64
Study 8936492 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight glucose infusion (5 mg.kg‐1.d‐1)
Number of subjects: 16
Study 8936492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucose infusion)
Number of subjects: 16
Study 1543310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine, 2 mg/kg body weight
Number of subjects: 18
Study 1543310 — intervention group
Group type: COMPARATOR
Intervention: Intranasal saline
Number of subjects: 18
Study 3904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 45
Study 3904464 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple injections
Number of subjects: 45
Study 3904464 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-injection treatment
Number of subjects: 45
Study 3113566 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental grading reported to the clinician responsible for care
Number of subjects: 2000
Study 3113566 — intervention group
Group type: COMPARATOR
Intervention: Placental grading noted but not reported
Number of subjects: 2000
Study 31289017 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intracoronary adenosine (360 mcg/min)
Number of subjects: 41
Study 31289017 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous adenosine (140-180 mcg/kg/min)
Number of subjects: 41
Study 29808819 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (DCB)
Number of subjects: 229
Study 29808819 — intervention group
Group type: COMPARATOR
Intervention: Second-generation sirolimus-eluting stent (DES)
Number of subjects: 229
Study 27692497 — intervention group
Group type: EXPERIMENTAL
Intervention: PHMB-based solution
Number of subjects: 40
Study 27692497 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (Control)
Number of subjects: 40
Study 25047826 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS with placebo gum
Number of subjects: 30
Study 25047826 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine gum with sham tDCS
Number of subjects: 30
Study 25047826 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with placebo gum
Number of subjects: 30
Study 22385548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical drink with red yeast rice (RYR)
Number of subjects: 79
Study 22385548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutraceutical drink without red yeast rice (RYR)
Number of subjects: 79
Study 22385548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 20878941 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based handrub
Number of subjects: 3317
Study 20878941 — intervention group
Group type: COMPARATOR
Intervention: Plain soap and water
Number of subjects: 3317
Study 19071988 — intervention group
Group type: EXPERIMENTAL
Intervention: Embedding mental action verbs within instructions
Number of subjects: 0
Study 16189492 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric soft contact lens (TS)
Number of subjects: 30
Study 16189492 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric soft contact lens (AS)
Number of subjects: 30
Study 16189492 — intervention group
Group type: COMPARATOR
Intervention: Spectacle correction (SC)
Number of subjects: 30
Study 12776225 — intervention group
Group type: EXPERIMENTAL
Intervention: General movements (GMs) assessment between 3 and 6 weeks
Number of subjects: 22
Study 12776225 — intervention group
Group type: EXPERIMENTAL
Intervention: General movements (GMs) assessment between 9 and 16 weeks
Number of subjects: 22
Study 12776225 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of early asymmetries at both 3-6 and 9-16 weeks
Number of subjects: 22
Study 12776225 — intervention group
Group type: COMPARATOR
Intervention: General movements (GMs) assessment
Number of subjects: 22
Study 10704160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 200
Study 10704160 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus Heparin
Number of subjects: 200
Study 10704160 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 200
Study 10704160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9346795 — intervention group
Group type: EXPERIMENTAL
Intervention: Piggyback with temporary portocaval shunting
Number of subjects: 44
Study 9346795 — intervention group
Group type: COMPARATOR
Intervention: Conventional liver transplantation with venovenous bypass
Number of subjects: 44
Study 8263618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium tocolysis
Number of subjects: 90
Study 8263618 — intervention group
Group type: COMPARATOR
Intervention: Conservative management with hydration, sedation, and observation
Number of subjects: 90
Study 8263618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (treatment and control)
Number of subjects: 90
Study 3518729 — intervention group
Group type: EXPERIMENTAL
Intervention: Treuphadol oblong tablets (500 mg paracetamol)
Number of subjects: 8
Study 3518729 — intervention group
Group type: EXPERIMENTAL
Intervention: Treuphadol Plus oblong tablets (500 mg paracetamol, 30 mg codeine phosphate)
Number of subjects: 8
Study 3518729 — intervention group
Group type: EXPERIMENTAL
Intervention: Treuphadol suppositories (750 mg paracetamol)
Number of subjects: 8
Study 3518729 — intervention group
Group type: COMPARATOR
Intervention: Commercial tablets (500 mg paracetamol)
Number of subjects: 8
Study 31103367 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Number of subjects: 32590
Study 31103367 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 32590
Study 30672176 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck-seven-acupoint group
Number of subjects: 90
Study 30672176 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture group
Number of subjects: 90
Study 30672176 — intervention group
Group type: COMPARATOR
Intervention: Medication group
Number of subjects: 90
Study 26091965 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched formula (600 mg daily)
Number of subjects: 138
Study 26091965 — intervention group
Group type: COMPARATOR
Intervention: High oleic acid sunflower seed oil (placebo)
Number of subjects: 138
Study 25517706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine for 25 days
Number of subjects: 1310
Study 25517706 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-replacement therapy for 8 weeks
Number of subjects: 1310
Study 25517706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 1310
Study 25517706 — intervention group
Group type: COMPARATOR
Intervention: Nicotine-replacement therapy
Number of subjects: 1310
Study 22853325 — intervention group
Group type: EXPERIMENTAL
Intervention: AR + IVR (Assisted Referral + Interactive Voice Recognition follow-up calls)
Number of subjects: 900
Study 22853325 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 900
Study 20821930 — intervention group
Group type: EXPERIMENTAL
Intervention: iobitridol 350
Number of subjects: 98
Study 20821930 — intervention group
Group type: COMPARATOR
Intervention: iopamidol 370
Number of subjects: 98
Study 17490963 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1) for 10 d followed by <50 mg choline x 70 kg(‐1) x d(‐1)
Number of subjects: 57
Study 17490963 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet containing 550 mg choline x 70 kg(‐1) x d(‐1)
Number of subjects: 57
Study 17490963 — intervention group
Group type: COMPARATOR
Intervention: Folic acid supplement (400 microg/d)
Number of subjects: 57
Study 17490963 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental amounts of choline added back to the diet
Number of subjects: 57
Study 16200680 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 100
Study 16200680 — intervention group
Group type: COMPARATOR
Intervention: IRM
Number of subjects: 100
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: SHARE sex education programme
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive teacher training
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatibility with existing Personal and Social Education (PSE) provision
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior management support
Number of subjects: 13
Study 11888044 — intervention group
Group type: EXPERIMENTAL
Intervention: Competition for curriculum time
Number of subjects: 13